Picture of AstraZeneca logo

AZN — AstraZeneca News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Brief: FDA Approves Durvalumab With Enfortumab Vedotin-Ejfv For Muscle Invasive Bladder Cancer

BRIEF-FDA Approves Durvalumab With Enfortumab Vedotin-Ejfv For Muscle Invasive Bladder Cancer

- FDA:

  • FDA APPROVES DURVALUMAB WITH ENFORTUMAB VEDOTIN-EJFV FOR MUSCLE INVASIVE BLADDER CANCER


((Reuters.Briefs@thomsonreuters.com;))

Recent news on AstraZeneca

See all news